Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Skylight and ClinEdge partner to begin clinical research in US

07 Apr 2021 (Last Updated April 16th, 2021 15:05)

Skylight Health Group has collaborated with ClinEdge to bring clinical research to primary care practices in Massachusetts, US.

Skylight and ClinEdge partner to begin clinical research in US
The partnership will bring clinical research trials investigating a wide range of indications to Skylight Health’s clinics beginning with Massachusetts. Credit: National Cancer Institute on Unsplash.

Skylight Health Group has collaborated with ClinEdge to bring clinical research to primary care practices in Massachusetts, US.

ClinEdge provides a full suite of services to support clinical research institutions, contract research organisations (CROs), and sponsors.

It aims to develop and increase service lines which positively affect the cost structure, timeliness as well as the accuracy of administering clinical research.

Skylight Health noted that the partnership with ClinEdge will bring clinical research trials investigating a wide range of indications to its clinics beginning with Massachusetts to accelerate growth in the field of research.

These indications include diabetes, Covid-19, arthritis, post-traumatic stress disorder, hypertension, among others.

Through this, patients in Massachusetts will have the opportunity to participate in these clinical trials that may provide access to new therapies, treatments or vaccines.

Skylight Health Digital Health and Research senior vice-president Christopher Smith said: “At Skylight Health we focus on continually improving the care of our patients through research, data, and innovation.

“This partnership represents an opportunity for our clinics and patients to make meaningful contributions to the improvement of healthcare through clinical research while providing access to new therapies and the potential for subsidiised care.”

Skylight Health also noted that the participation in these clinical trials will be available for existing patients as well as individuals who may not be the company’s patients but are interested in contributing to research.